About the Company
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CNAT News
Conatus Pharmaceuticals (CNAT) Stock Soars on Positive Liver Drug Trial Results
Conatus Pharmaceuticals (CNAT) stock is increasing in mid-morning trading on Wednesday after the company said a Phase 2 trial of its liver drug showed positive results. Conatus Pharmaceuticals ...
Todd Foley's Net Worth
Todd Foley has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., iTeos Therapeutics, Inc., TriVascular ...
MPM BIOVENTURES V, L.P.'s Net Worth
Who is MPM BIOVENTURES V, L.P.? MPM BIOVENTURES V, L.P. has an estimated net worth of $192 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS ...
KPRX Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead ...
Ionis Pharmaceuticals Inc IONS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Amylyx Pharmaceuticals Inc AMLX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Amneal Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?
With the business potentially at an important milestone, we thought we'd take a closer look at Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) future prospects. Tarsus Pharmaceuticals, Inc., a ...
UPC Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers ...
Q4 2023 Ionis Pharmaceuticals Inc Earnings Call
Brett P. Monia; Founder, CEO & Director; Ionis Pharmaceuticals, Inc. D. Wade Walke; SVP of IR; Ionis Pharmaceuticals, Inc. Elizabeth L. Hougen; Executive VP of ...
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus.
Loading the latest forecasts...